De novo design TNF-alpha antagonistic peptide based on the complex structure of TNF-alpha with its neutralizing monoclonal antibody Z12

Journal of Biotechnology
Weisong QinBeifen Shen

Abstract

Tumor necrosis factor-alpha (TNF-alpha) antagonists have become therapeutic drugs for immunological diseases including rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, etc. Low molecular weight synthetic peptides can mimic the binding sites of TNF-alpha receptors and block the activity of TNF-alpha. Based on the 3-D complex structure of TNF-alpha with its neutralizing monoclonal antibody (Mab) Z12, an antagonistic peptide (AP) was rationally de novo designed. The designed AP possessed similar structural character and potential bioactivity with Mab Z12. AP could competitively inhibit the binding of Mab Z12 to TNF-alpha, TNF-alpha-meditated caspase activation and TNF-alpha-induced cytotoxicity on murine L929 cells with a dose-dependent fashion. This study highlights the potential of computation-aided method for the design of novel peptides with the ability to block the deleterious biological effects of TNF-alpha.

References

Oct 30, 1992·Biochemical and Biophysical Research Communications·B L LieN Numao
Apr 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·M LewisD V Goeddel
Apr 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M BrockhausH Loetscher
Apr 1, 1986·Immunological Reviews·T Kieber-Emmons, H Kohler
Sep 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·W V WilliamsM I Greene
Jul 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·W V WilliamsM I Greene
Jan 1, 1989·Annual Review of Immunology·B Beutler, A Cerami
Sep 1, 1989·Immunology Today·F R Balkwill, F Burke
Jun 27, 1996·The New England Journal of Medicine·F Bazzoni, B Beutler
Jan 19, 2000·Trends in Pharmacological Sciences·S I Taylor
Jul 13, 2000·Microscopy Research and Technique·M J Smyth, R W Johnstone
Nov 30, 2000·The New England Journal of Medicine·P E LipskyUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
Mar 13, 2001·Annual Review of Immunology·M Feldmann, R N Maini
Oct 13, 2001·The New England Journal of Medicine·J KeaneM M Braun
May 30, 2002·Nature Reviews. Immunology·Marc Feldmann
Oct 3, 2002·Annual Review of Medicine·Raphaela Goldbach-Mansky, Peter E Lipsky
Nov 19, 2002·Clinics in Dermatology·Ronni WolfVincenzo Ruocco
Feb 28, 2003·Clinical Rheumatology·M DebandtO Meyer
Apr 30, 2003·Expert Opinion on Biological Therapy·Jürgen Braun, Joachim Sieper
May 29, 2003·Dermatology : International Journal for Clinical and Investigative Dermatology·S A DevosJ M Naeyaert
Aug 2, 2003·Journal of the American Academy of Dermatology·Ben Goffe, Jennifer Clay Cather
Nov 25, 2003·The New England Journal of Medicine·Craig L LeonardiUNKNOWN Etanercept Psoriasis Study Group
May 29, 2004·Gastroenterology·Paul RutgeertsSéverine Vermeire
Jun 18, 2004·The New England Journal of Medicine·James R O'Dell
Sep 1, 2004·Biochemical and Biophysical Research Communications·Weisong QinBeifen Shen
May 10, 2005·Molecular Immunology·Weisong QinBeifen Shen
Apr 1, 1986·Journal of Computational Chemistry·Scott J WeinerDavid A Case

❮ Previous
Next ❯

Citations

Dec 18, 2007·Preparative Biochemistry & Biotechnology·Shusheng GengBeifen Shen
May 9, 2007·Molecular Immunology·Hong ChangBeifen Shen
Jun 11, 2015·Immunologic Research·Shusheng GengBeifen Shen
Aug 8, 2014·Journal of the Royal Society, Interface·Angela Maria CusanoPaolo Antonio Netti
Jun 5, 2015·Technology in Cancer Research & Treatment·Xinying LiYan Li
Dec 6, 2020·Biochemical and Biophysical Research Communications·Keita TsukamotoTakashi Kawakami

❮ Previous
Next ❯

Related Concepts

Related Feeds